-
公开(公告)号：KR102012837B1
公开(公告)日：2019-08-21
申请号：KR1020170119564
申请日：2017-09-18
Applicant: 중앙대학교 산학협력단
IPC: G01N33/68 , G01N33/50 , A61K48/00 , A61K31/713 , A61K39/395
-
公开(公告)号：KR101465403B1
公开(公告)日：2014-11-26
申请号：KR1020140084695
申请日：2014-07-07
Applicant: 중앙대학교 산학협력단
IPC: G01N33/53 , G01N33/574 , C07K14/435 , A61K38/17
Abstract: 본 발명은 SET/TAF-Iβ 및 Ku70/80 결합을 이용한 항암제 스크리닝 방법에 관한 것으로서, 상세하게는 SET/TAF-Iβ 및 Ku70/80 결합을 촉진하는 후보약물을 선별하는 단계를 포함하는 항암제 스크리닝 방법을 제공한다. 한편, INHAT 복합체의 서브유닛인 SET/TAF-1β가 Ku70/80과 결합하고, 상기 결합이 CBP- 및 PCAF-매개 Ku70 아세틸화를 억제한다는 것을 확인하고, DNA가 손상되면 SET/TAF-1β와 Ku70/80의 결합을 방해하므로, 상기 결합을 이용하여 DNA 손상과 관련된 질환인 암을 치료할 수 있는 항암제 스크리닝 방법으로 유용하게 사용될 수 있다.
Abstract translation: 本发明涉及通过使用SET / TAF-Iβ和Ku70 / 80的组合来筛选抗癌剂的方法，更具体地说，涉及一种筛选抗癌剂的方法，包括选择促进SET / TAF-Iβ和Ku70 / 80。 同时，作为INHAT复合物的亚单位的SET / TAF-1β与Ku70 / 80组合，组合抑制CBP和PCAF介导的Ku70的乙酰化。 当DNA受损时，SET / TAF-1β和Ku70 / 80的组合被破坏。 因此，本发明可以用作筛选使用该组合来治疗与DNA损伤有关的癌症的抗癌剂的方法。
-
公开(公告)号：KR101304034B1
公开(公告)日：2013-09-04
申请号：KR1020110056875
申请日：2011-06-13
Applicant: 중앙대학교 산학협력단
IPC: G01N33/53 , G01N33/68 , G01N33/574
Abstract: 본 발명은 JMJD1B (jumonji domain containing 1B)유전자, 이의 전사체 또는 발현된 단백질을 포함한 백혈병 진단용 조성물을 제공한다. 보다 구체적으로, 상기 JMJD1B의 전사, 단백질 발현 또는 단백질 활성을 억제하면 암 유전자의 활성이 억제되고 세포자살 유전자를 활성화시켜 백혈병 치료에 효과가 있으므로, 상기 유전자, 유전자의 전사나 발현, 활성을 조절함으로 백혈병 진단제, 약물 스크리닝 등이 가능하고, 본 발명의 유전자를 백혈병 치료 타겟으로 활용할 수 있을 것이다.
-
公开(公告)号：KR1020120137803A
公开(公告)日：2012-12-24
申请号：KR1020110056875
申请日：2011-06-13
Applicant: 중앙대학교 산학협력단
IPC: G01N33/53 , G01N33/68 , G01N33/574
Abstract: PURPOSE: A composition containing JMJD1B gene, a transcript thereof, or proteins expressed from the same is provided to suppress oncogene activation and to treat leukemia. CONSTITUTION: A composition for diagnosing leukemia contains JMJD1B(jumonji domain containing 1B) encoding an amino acid of sequence number 1, a transcript thereof, or protein expressed from the same. The JMJD1B protein has histone dimethylase H3K9-me1/2 activity. A method for screening a therapeutic agent for treating leukemia comprises a step of contacting the gene, transcript, or protein as a target material with a test material; a step of identifying a reaction of the target material and the test material; and a step of determining the gene transcription or protein expression or activation.
Abstract translation: 目的：提供含有JMJD1B基因，其转录物或由其表达的蛋白质的组合物以抑制癌基因激活和治疗白血病。 构成：用于诊断白血病的组合物含有编码序列号1的氨基酸的JMJD1B（含有1B的Jumonji结构域），其转录物或由其表达的蛋白质。 JMJD1B蛋白具有组蛋白二甲基酶H3K9-me1 / 2活性。 用于筛选用于治疗白血病的治疗剂的方法包括使作为靶材料的基因，转录物或蛋白质与测试材料接触的步骤; 识别目标材料和测试材料的反应的步骤; 以及确定基因转录或蛋白质表达或活化的步骤。
-
公开(公告)号：KR1020120136909A
公开(公告)日：2012-12-20
申请号：KR1020110056111
申请日：2011-06-10
Applicant: 중앙대학교 산학협력단
CPC classification number: A61K38/1706 , A61K38/1764 , A61K48/005 , C07K14/461 , C07K14/4748 , C07K2317/73
Abstract: PURPOSE: A method and a pharmaceutical composition for inducing cell apoptosis are provided to overexpress proteins containing SET domains and to lower cell viability. CONSTITUTION: A method for inducing cell apoptosis comprises a step of overexpressing proteins containing SET domains of amino acid sequence number 1. The proteins are setd3 of sequence number 2. A pharmaceutical composition for inducing cell apoptosis contains the proteins or a gene encoding the same as an active ingredient. The pharmaceutical composition is used for preventing and treating cancer, diabetes, artheriosclerosis, inflammatory bowel diseases, autoimmune diseases, transplantation rejection, post-traumatic immune response, infectious diseases, lymphatic tumor, multiple sclerosis, SLE, pachydermia, ischemia, stroke, uveitis or diabetic retinopathy.
Abstract translation: 目的：提供一种用于诱导细胞凋亡的方法和药物组合物，其过表达含有SET结构域的蛋白质并降低细胞活力。 构成：诱导细胞凋亡的方法包括过表达含有氨基酸序列1的SET结构域的蛋白质的步骤。将蛋白质设置为序列号2。用于诱导细胞凋亡的药物组合物含有蛋白质或编码与 活性成分。 该药物组合物用于预防和治疗癌症，糖尿病，动物硬化症，炎症性肠病，自身免疫疾病，移植排斥反应，创伤后免疫应答，感染性疾病，淋巴瘤，多发性硬化，SLE，皮痛，缺血，中风，葡萄膜炎或 糖尿病性视网膜病变。
-
Patent Agency Ranking16.发明公开원 종양유전자 단백질 ＤＥＫ를 이용하여 세포사멸을유도하는 조성물 및 방법 및 ＤＥＫ를 발현하는 형질전환초파리 有权一种组合物和一种用于诱导癌细胞使用DEK过表达和乳头状血红蛋白过度表达的方法
公开(公告)号：KR1020090036028A
公开(公告)日：2009-04-13
申请号：KR1020070101113
申请日：2007-10-08
Applicant: 중앙대학교 산학협력단 , 재단법인서울대학교산학협력재단
CPC classification number: A61K48/0058 , Y10S514/885
Abstract: An anti-cancer composition containing DEK proteins or nucleic acid coding the DEK proteins is provided to induce apoptosis and inhibit dysplasia of cancer cells by overexpressing DEK to increase caspase-dependent apoptosis. An anti-cancer composition for inducing apoptosis comprises DEK proteins having amino acid sequence of SEQ ID NO:2 or nucleic acid for coding DEK protein having base sequence of SEQ ID NO:1. A transformed drosophila is prepared to overexpress the DEK proteins. The transformed drosophila is obtained by a pUAS-hDEK recombinant vector containing the nucleic acid for coding the DEK proteins. The anti-cancer composition containing the DEK proteins or the nucleic acid coding the DEK proteins is used for treating or preventing cancer.
Abstract translation: 提供含有DEK蛋白或编码DEK蛋白的核酸的抗癌组合物以通过过表达DEK诱导细胞凋亡和抑制癌细胞发育异常增加胱天蛋白酶依赖性细胞凋亡。 用于诱导凋亡的抗癌组合物包含具有SEQ ID NO：2的氨基酸序列的DEK蛋白或用于编码具有SEQ ID NO：1的碱基序列的DEK蛋白的核酸。 一种转化的果蝇准备过表达DEK蛋白。 转化的果蝇由含有用于编码DEK蛋白的核酸的pUAS-hDEK重组载体获得。 含有DEK蛋白的抗癌组合物或编码DEK蛋白的核酸用于治疗或预防癌症。
-
公开(公告)号：KR1020090035808A
公开(公告)日：2009-04-13
申请号：KR1020070100793
申请日：2007-10-08
Applicant: 중앙대학교 산학협력단 , 재단법인서울대학교산학협력재단
Abstract: A nucleic acid is provided to quickly and simply diagnose whether leukemia exists or not regardless of leukemia types using by being used as a leukemia diagnosis marker. A nucleic acid for leukemia diagnosis comprises base sequence of SEQ ID NO:1 or complementary base sequence thereof or can be specifically coupled with the base sequence of SEQ ID NO:1 or the complementary base sequence thereof. An oligonucleotide chip for leukemia diagnosis contains the nucleic acid for leukemia diagnosis. A method for diagnosing leukemia has a step of measuring existence of expression of RE-IIBP(response element-II binding protein) in monocyte of marrow or measuring existence of methylation of histone protein in the monocyte of marrow.
Abstract translation: 提供核酸以快速和简单地诊断白血病是否存在，而不管白血病类型如何用作白血病诊断标记。 用于白血病诊断的核酸包括SEQ ID NO：1的碱基序列或其互补碱基序列，或者可以与SEQ ID NO：1的碱基序列或其互补碱基序列特异性偶联。 用于白血病诊断的寡核苷酸芯片包含用于白血病诊断的核酸。 诊断白血病的方法具有测定骨髓单核细胞中RE-IIBP（应答元件-II结合蛋白）表达的存在或测定骨髓单核细胞中组蛋白甲基化的存在的步骤。
-
-
公开(公告)号：KR102108414B1
公开(公告)日：2020-05-11
申请号：KR1020190089577
申请日：2019-07-24
Applicant: 중앙대학교 산학협력단
IPC: C12N9/12 , C12N9/02 , G01N33/574 , G01N33/53 , C12Q1/6886
-
公开(公告)号：KR101976940B1
公开(公告)日：2019-05-09
申请号：KR1020170109824
申请日：2017-08-30
Applicant: 중앙대학교 산학협력단
IPC: C12N15/113 , C12N5/071
-
-
-
-
-
-
-
-
-
Search Results
28
records
(took 0.029 seconds)
